Aurora Cannabis (ACB) in focus as Curaleaf (CURLF) tables unsolicited $4-per-share bid
Curaleaf's unsolicited $4-per-share cash-and-stock bid for Aurora Cannabis (ACB) landed on Aug. 11, after private acquisition talks between the two companies broke down and the U.S. multi-state operator said it would take the proposal directly to Aurora shareholders. Curaleaf (CURLF) formed a special committee to review the offer before that approach. Aurora's board has not accepted the terms, and the next definable event is a formal response from ACB's directors.
Key takeaways
- Curaleaf (CURLF) made an unsolicited $4-per-share cash-and-stock bid for Aurora Cannabis (ACB) on Aug. 11 after private acquisition talks broke down.
- Aurora's board has not accepted the offer, calling the price too low and below levels ACB traded at as recently as December 2025.
- Curaleaf says the combined company would span 17 countries with over $1.5 billion in annual revenue and at least $40 million in annual cost savings.
- Aurora shares traded around $3.48 at the time of the report, a discount to the $4 offer, while Curaleaf shares closed Tuesday about 6% higher.
- The next key event is a formal response from Aurora's board and any amended terms from Curaleaf.
Curaleaf's unsolicited $4-per-share cash-and-stock bid for Aurora Cannabis (ACB) landed on Aug. 11, after private acquisition talks between the two companies broke down and the U.S. multi-state operator said it would take the proposal directly to Aurora shareholders. Curaleaf (CURLF) formed a special committee to review the offer before that approach. Aurora's board has not accepted the terms, and the next definable event is a formal response from ACB's directors.
Aurora shares were trading around $3.48 at the time of the source report, a discount to the proposed $4. Even with the session move, ACB is still down roughly 10% from the start of the year. Curaleaf shares ended Tuesday about 6% higher.
The strategic logic Curaleaf offered is specific. The acquisition, as the company described it, would create a combined business spanning 17 countries with over $1.5 billion in annual revenue and at least $40 million in annual cost savings. The international footprint is the point: the deal would accelerate Curaleaf's expansion into European medical cannabis markets, including Germany, Poland, and the UK. Aurora's recently acquired Safari Flower Company brings EU-GMP certified cultivation facilities and adds over 50 tons of annual production capacity.
Aurora's board has already signaled the price is too low, noting the proposed valuation falls below levels ACB traded at as recently as December 2025. Wall Street analysts have said the bid undervalues Aurora's long-term medical business. Heading into Aug. 11, the consensus rating on ACB was "Moderate Buy," and price targets reached as high as $5.71.
That analyst ceiling matters for the tape. If Curaleaf holds at $4 and Aurora declines without a higher competing bid materializing, the stock gives those session gains back. Watch for Aurora's formal board response and any amended terms from Curaleaf.
Related reading
Filed by the newsroom of MarketPR on August 14, 2026. Source: finance.yahoo.com. Indicative figures are not investment advice.